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Abstract 
The aim of this study was to identify shifts in antimicrobial resistance in the Hampshire region including correlations 
between patient demographic and antibiotic prescribing to inform safe and effective antimicrobial stewardship. 475 
ESBL and AmpC producing bacteria, from various infection sites, were obtained from four hospital laboratories in 
Hampshire, UK, during 2010 and 2012. All isolates were identified to species level. ESBL production and antimicrobial 
susceptibility testing was performed using disc diffusion methodology. Multiplex PCR and gel electrophoresis was used to 
detect the BlaCTX, BlaTEM and BlaSHV resistance determinants. Corresponding patient data included patient age, gender, 
location, clinical details and previous antibiotic therapy. Patient information revealed mean ages of 60 and 62 for the 
2010 and 2012 cohorts respectively, with ages ranging from 3 months to 96. ESBL production was the most prevalent 
resistance mechanism (65% in 2010, 79% in 2012), produced mostly by E.coli (85% in 2010, 84% in 2012). While 9 of 
the 13 antibiotics demonstrated increased resistance, 4 demonstrated a decrease. CTX was the most prevalent resistance 
determinant (38% in 2010 and 27% in 2012), followed by dual expression of CTX & TEM, TEM, TEM & SHV, SHV, SHV & 
CTX and all three resistance determinants. A significant correlation between patient age and joint expression of TEM & 
SHV was observed in 2010, in 2012, patient age significantly correlated with joint CTX and SHV expression. Significant 
differences could also be determined between resistance determinant type and antimicrobial resistance. This study 
shows that the incidence of ESBL and AmpC infections and resistance to commonly used antibiotics within Hampshire is 
increasing both within the hospital and community setting. This emphasises the need for judicious antibiotic prescribing 
to safeguard this valuable medical commodity. 
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Introduction 
Since the emergence of extended spectrum beta-
lactamase (ESBL) producing organisms in 1983 [1] their 
prevalence has continued to rise worldwide contributing 
significantly to antimicrobial resistance. These plasmid 
mediated bacterial enzymes provide resistance to early 
and third generation cephalosporins and monobactams. 
They can be found in Gram negative organisms especially 
Enterobacteriaceae [2]. ESBL groups have been classified 
according to their amino-acid sequences. Those first 
described were derivatives of the beta-lactamase 
enzymes TEM-1, TEM-2 and SHV-1; further mutations 
within these classes have since been identified with more 
than 160 and 100 variants respectively. Studies indicate 
the distribution of TEM and SHV ESBL resistance are now 
worldwide [3]. In addition, a new family of ESBL 
producing bacteria was identified in 1989 called CTX-M 
due to the enzyme conferring resistance to cefotaxime 
instead of ceftazidime. Since its discovery there has been 
over 65 variants of the CTX-M enzyme identified [3].  
 
Until recently most infections caused by ESBL 
producing bacteria have been reported as nosocomially 
related, posing as a risk to 
hospitalised/Immunocompromised patients [4]. 
However, further evidence now suggests that ESBL 
producing organisms may be an emerging threat to the 
general practitioner or outpatient setting [5]. A study 
published in 2001 (Israel), analysing the antimicrobial 
susceptibility patterns of 8338 community urinary 
pathogens, found that 1% of the Gram Negative isolates 
produced ESBL resistance [6]. A further study completed 
in Spain during 2002 isolated CTX-M ESBL producing 
E.coli from seven patients suffering urinary tract 
infections who had never been admitted to hospital [7]. 
Studies in Sweden during 2008 and 2010 investigated the 
prevalence of faecal ESBL carriage in patients from the 
community and within a hospital setting. Results during 
2008 illustrated rates of 2.1% within the primary health 
care units and 1.8% within hospitalised patients. In 2010 
results identified a further raise of faecal carriage with 
rates of 3% within primary health care units and 6.8% 
within hospitalised patients [8]. Thus, the evident rise in 
carriage and isolation of ESBL producing organisms both 
within hospitalised and community patients are likely to 
limit treatment options.  
 
Empirical therapy prescribed during the clinical 
diagnosis is often inadequate resulting in failure or delay 
in treatment, leading to a rise in mortality rates [9]. 
Agents illustrating susceptibility to ESBL producing 
Enterobacteriaceae include cephamycins (cefoxitin and 
cefotetan); however reluctance to prescribe these 
therapies is due to the ease in which isolates can incur 
resistance [10]. Currently carbapenems including 
imipenem, meropenem and ertapenem are chosen as the 
drug of choice to treat serious ESBL infections. As the 
numbers of ESBL infections and use of carbapenems rise, 
concerns include the potential risk of carbapenem 
resistant mutants [11]. Although rare, resistance has 
emerged with carbapenem resistant ESBL producing 
Enterobacteriaceae reported in a range of settings 
including a hospital in New York [12] and a tertiary 
medical centre in Israel [13]. 
 
The aim of this two year in-depth study was to 
evaluate the ESBL profile, including antimicrobial 
resistance patterns and resistance determinant 
identification, of isolates collected from four hospitals in 
the Hampshire region during 2010 and 2012. Evaluation 
of results would identify shifts in antimicrobial resistance 
and potential relationships between the patient 
demographic, antibiotic prescribing and ESBL infection.  
 
Materials and Methods 
Ethics 
Full ethical considerations were given to the collection 
of bacteria, due to all patient details being anonymised at 
the point of collection, ethical approval was provided by 
the University of Portsmouth's Ethical Review Committee.  
 
Patient Demographics 
The following anonymised patient details were 
recorded: age, gender, clinical details, antibiotic history 
and physical location and are detailed in Table 2. 
 
Bacterial Isolates 
A total of 475 ESBL and/or AmpC producing bacteria 
collected from various infection sites, were obtained from 
four hospital laboratories in Hampshire. Isolates were 
collected on nutrient agar slopes (Oxoid).  
 
Identification and Antimicrobial Susceptibility 
Testing 
All isolates were identified to species level using a 
beta-galactosidase PCR [14], for the identification of E.coli 
[14] (Table 1) and the API20e system (Biomerieux). ESBL 
production was detected using the D68C AMPC and ESBL 
detection method (MAST). Antimicrobial susceptibility 
testing was performed according to the British Society of 
Antimicrobial Chemotherapy (BSAC) and European 
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Committee on Antimicrobial Susceptibility Testing 
(EUCAST) guidelines (Gentamicin 10µg/ml, Cefotaxime 
30µg/ml, Amoxicillin 10µg/ml, Augmentin 30µg/ml, 
Cefuroxime 30µg/ml, Piperacillin-Tazobactam 
75/10µg/ml, Ciprofloxacin 1µg/ml, Meropenem 10µg/ml, 
Ertapenem 10µg/ml, Ceftazidime 10µg/ml, Amikacin 
30µg/ml, cefepime 30µg/ml and Tigecycline 15µg/ml) 
[15].  
 
Preparation of Bacterial DNA and PCR 
Amplification 
DNA was prepared using a boiling technique; a single 
bacterial colony was suspended in 50µl of sterile distilled 
water and heated at 95°C for 3 minutes, then spun, for 5 
minutes at 13000g at room temperature. The supernatant 
was removed for PCR analysis. BlaCTX, BlaTEM and BlaSHV 
genes were detected using multiplex PCR [16] (Table 1). 
PCR amplification conditions were as follows: initial 
denaturation step 95°C for 15 minutes; 30 cycles of 
denaturation at 95°C for 30 seconds, annealing at 54°C for 
30 seconds, extension at 72°C for 2 minutes followed by a 
final extension at 72°C for 10 minutes. PCR products were 
separated on a 1% agarose gel, stained with red safe stain 
(Invitrogen) in 1xTAE buffer and visualised using a bench 
top UV system (Alpha Digi Doc). 
 
Primer Name Sequence 5’ to 3’ Tm Amplicon Size 
BlaSHV Forward ATGCGTTATATTCGCCTGTG 45 747 
BlaSHV Reverse TGCTTTGTTATTCGGGCCAA 45 747 
BlaTEM Forward TCGCCGCATACACTATTCTCAGAATGA 53 445 
BlaTEM Reverse ACGCTCACCGGCTCCAGATTTAT 53 445 
BlaCTX Forward ATGTGCAGYACCAGTAARGTKATGGC 54 593 
BlaCTX Reverse TGGGTRAARTARGTSACCAGAAYCAGCGG 54 593 
Beta-Galactosidase 1 CTTTGCCTGGTTTCCGGCACCAGAA 60 762 
Beta-Galactosidase 2 AACCACCGCACGATAGAGATTCGGG 60 762 
Table 1: Primers used for PCR amplification. 
 
Statistical Analysis 
Statistical significance was assessed using the 
Spearman correlation, Kruskal-Wallis and Mann-Whitney 
tests, where appropriate as indicated in the text. Values of 
P<0.05 were deemed statistically significant. All statistical 
analysis was performed using the software programmes 
Microsoft Excel and Graphpad Prism version 6.01 for 
Windows 7.  
 
Results 
Patient Demographic 
The demographic profile of patients included in this 
study is detailed in Table 2. 
 
Patient Age 
Although samples were obtained from patients 
ranging in age from 3 months to >90 years, our 
demographic analysis indicates that patients over the age 
of 50 had a higher incidence of ESBL infections (Table 2).  
 
Patient Gender 
A significantly greater proportion of the patients 
suffering from ESBL infections were female (Table 2). It 
was unclear whether this sex-specific effect is a reflection 
of some inherent vulnerability of female patients or the 
preponderance of specific types of infections in this 
gender, hence our further analyses of the site of infection.  
 
Infection Site 
The most prevalent infection site was the urinary tract 
(UTI), Table 2. Within this patient group a higher 
proportion of females were observed compared to males, 
nevertheless this difference was not considered 
statistically significant P0.333. Other infection sites 
included wounds, with an equal gender ratio observed in 
2010 and a 2:1 ratio of males to females in 2012; systemic 
infections, from females alone in 2010 and a 1:2 ratio 
between males and females in 2012; respiratory tract 
infections, from males alone in both year groups and 
genital infections from female patients. 
 
Patient Location 
The patient demographic information collected within 
both year groups revealed that the majority of isolates 
were collected within the GP setting. The in-patient 
setting was the second most common patient location, 
followed by accident and emergency and the intensive 
care unit (ICU). Within 2010, in addition to the locations 
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previously mentioned, isolates were collected from the 
outpatient setting, the antenatal department and from the 
ministry of defence (Table 2).  
 
Previous Antimicrobial Therapy 
In order to determine if patients with a history of 
previous antimicrobial therapy were at an increased risk 
of ESBL resistance or if an agent outside of the prescribing 
guidelines had been prescribed, details of patients’ 
previous antibiotic therapy were collected. Within both 
year sets a high proportion of patients (70% of the total 
for 2010 and 74% for 2012) had not recently received an 
antibiotic, according to the sample request form received 
within the clinical laboratory. Further analysis of this 
patient set revealed that in both year groups, a high 
percentage of patients (76% in 2010 and 79% in 2012) 
who had not received any antimicrobial therapy 
presented within the community setting (GP, hospital 
outpatients or the accident and emergency department). 
Notably, although not statistically significant (P0.33), the 
mean age for these patients within each year (55 in 2010 
and 59 in 2012) was lower than the mean age for the total 
years (60 and 62). In contrast a smaller number of 
patients were reported as not receiving antimicrobial 
therapy within the inpatient environment (24% in 2010 
and 21 % in 2012). The mean age, although not 
statistically significant (P0.33), was higher (71 in 2010 
and 66 in 2012) compared to the mean year age listed 
above. Of those patients who were currently prescribed 
or had recently received antibiotics, 55% (n=49), (2010) 
and 50% (n=41), (2012) presented in the community 
setting. Within this group of patients, in 2010, 54% 
(n=26) had recently received or were currently 
prescribed an antibiotic outside of the current prescribing 
guidelines. Within 2012, this figure had reduced, to 28% 
(n=11). A similar picture could be seen when analysing 
the information obtained from the inpatient setting (59% 
(n=29) of patients in 2010 and 38% (n=16) of patients in 
2012). 
 
Criteria Prevalence 2010 Prevalence 2012 
Patient Details   
Average age of patients 60 (+/- 1.6 SEM) 62 (+/- 1.6 SEM) 
Median age (range) 1-96 3 months – 96 
Females 78% (n=179) 77% (n=191) 
Males 22% (n=50) 23% (n=57) 
Patient Location   
General Practitioner Surgery 61% (n=140) 77% (n=191) 
In Patient 27% (n=62) 20% (n=50) 
Accident and Emergency 7% (n=16) 2% (n=5) 
Out Patients 2% (n=5) - 
Intensive Care Unit 1% (n=2) 1% (n=2) 
Antenatal Clinic 1% (n=2) - 
Ministry of Defence 1% (n=2) - 
Site of Infection   
Urine 96% (n=218) 94% (n=234) 
Wound 2% (n=5) 3% (n=8) 
Blood Culture 1% (n=2) 1% (n=2) 
Sputum 1% (n=2) 1% (n=2) 
Genital Swab 1% (n=2) 1% (n=2) 
Previous Antibiotic Therapy   
No Therapy 70% (n=160) 74% (n=184) 
Previous Therapy 30% (n=69) 26% (n=64) 
No Therapy – Community Patients 76% (n=125) 79% (n=155) 
Previous Therapy – Community Patients 24% (n=40) 21% (n=41) 
No Therapy – In Patients 24% (n=15) 21% (n=11) 
Previous Therapy – In Patients 76% (n=49) 79% (n=41) 
Table 2: Patient demographic comparison between the two year groups. 
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Microbiological Analysis 
Organism Identification: Isolate identification revealed 
that E.coli was the most prevalent organism producing 
ESBL resistance in this study. Other bacterial species 
identified included Klebsiella pneumoniae, Enterobacter 
cloacae, Klebsiella oxytoca, Proteus mirabilis, Citrobacter 
freundii, Enterobacter aerogenes, Pantoea sp, Citrobacter 
braakii, Morganella morganii, and Stenotrophomonas 
maltophilia (Table 3). 
 
Resistance Mechanism: ESBL production was the most 
prevalent resistance mechanism expressed (Table 3), 
AmpC production was prevalent to a lesser extent and 3% 
of the isolates within 2010 and 4% of the isolates within 
2012, demonstrated expression of both ESBL and AmpC 
resistance. A proportion of isolates (23% (53) in 2010 
and 11% (24) in 2012) required further analysis to 
confirm ESBL or AmpC expression. Of these isolates, 85% 
(n=45) and 67% (n=16) exhibited positive DNA analysis 
for the presence of ESBL resistance determinants. There 
were no significant differences between the resistance 
type and hospital site, indicating that there is no 
association between ESBL or AmpC based infection, for 
any particular year, and location (P>0.05; Kruskal-Wallis). 
 
There were also no significant differences between the 
identified resistance type compared to the patient gender 
(P>0.05; Mann Whitney) and patient age (P>0.05; Kruskal 
Wallis).  
 
Comparing the percentage of each resistance type 
according to the patient age range revealed similarities 
between age groups 11-20, 21-30, 31-40, 51-60 and 61-
70 in 2010 and age groups 21-30, 31-40, 41-50 and 61-70 
in 2012 suggesting that these age groups have an equal 
risk of ESBL and AmpC producing organisms (Figure 1). 
While in 2010, a high prevalence of ESBL resistance was 
detected across all age ranges, significantly lower levels of 
prevalence for AmpC and dual resistance was detected 
across all age ranges with the exception of age groups 11-
20 and 21-30 (Figure 1A). This profile was consistent in 
isolates from 2012 (Figure 1B).  
 
Organism Identification Prevalence 2010 Prevalence 2012 
Escherichia coli 85% (n=195) 84% (n=208) 
Klebsiella pneumoniae 6% (n=13) 4% (n=10) 
Enterobacter cloacae 3% (n=7) 6% (n=15) 
Klebsiella oxytoca 3% (n=7) 1 isolate 
Proteus mirabilis 1% (n=2) 2% (n=4) 
Enterobacter aerogenes 1% (n=2) 1% (n=2) 
Citrobacter fruendii 1 isolate 2% (n=4) 
Pantoea sp 1% (n=2) - 
Citrobacter braakii - 1 isolate 
Morganella morganii  1% (n=2) 
Stenotrophomonas maltophilia -  1 isolate 
Resistance Mechanism   
ESBL 65% (n=148) 79% (n=196) 
AmpC 9% (n=21) 6% (n=15) 
ESBL and AmpC 3% (n=7) 4% (n=10) 
Further Analysis to confirm resistance mechanism 23% (n=53) 11% (n=27) 
Table 3: Organism and resistance mechanisms prevalence in 2010 and 2012. 
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(a)                                                                                                                 (b) 
Figure 1 (a): The percentage ESBL, AmpC and Dual resistance in each age group of patients within 2010. The graph 
illustrates that an equal risk or no risk of AmpC or dual resistance could be identified within the age groups 11-20, 21-
30, 31-40, 51-60 and 61-70. Age ranges 1-10, 71-80 and 91-96 also illustrated higher percentage of AmpC resistance; 
(b) the percentage ESBL, AmpC and Dual resistance in each age group of patients within 2012. The graph illustrates 
that an equal risk or no risk of AmpC or dual resistance could be identified within the age groups 21-30, 31-40, 41-50, 
61-70 and 91-98. Age range 1-10 illustrated a higher percentage of AmpC resistance.  
 
 
Antimicrobial Susceptibility Investigations 
Antimicrobial susceptibility investigations revealed 
that amoxicillin exhibited the highest resistance within 
both year sets; in contrast meropenem demonstrated the 
highest sensitivity. When comparing the resistance 
percentages for each year group, 9 of the 13 antibiotics 
demonstrated increased resistance between 2010 and 
2012, these included amoxicillin, augmentin, meropenem, 
cefotaxime, ertapenem, ceftazidime, tigecycline, 
cefuroxime and gentamicin. In comparison four of the 
antibiotics demonstrated a decrease in resistance 
between the two year groups these included cefepime, 
ciprofloxacin, piperaillin-tazobactam and amikacin 
(Figure 2).  
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Figure 2: Comparison of percentage resistance, intermediate resistance and sensitivity for each agent within each year 
group.  
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Results illustrate that amoxicillin has the highest and 
meropenem the lowest resistance rates. An increase in 
antimicrobial resistance could be identified in amoxicillin, 
co-amoxiclav, meropenem, cefotaxime, ertapenem, 
ceftazidime, tigecycline, cefuroxime and gentamicin. In 
contrast a decrease in antimicrobial resistance could be 
identified in cefepime, ciprofloxacin, piperaillin-
tazobactam and amikacin. 
 
In order to determine if resistance to specific 
antimicrobial agents was restricted to or illustrated 
higher levels within individual hospitals and was perhaps 
influenced by antimicrobial prescribing policies, each 
hospital’s resistance, intermediate resistance and 
susceptibility percentages were calculated for each year 
cohort (Figures 3A and 3B). Comparing the resistance 
percentages for each hospital, two hospitals 
demonstrated an increased resistance in augmentin 
between the years 2010 and 2012 (42% and 38% 
increase). Ertapenem resistance was identified within two 
hospitals, with a 5% and 2% increase between 2010 and 
2012 and gentamicin resistance also appeared to increase 
in three of the hospitals (7%, 10% and 28% increases). 
Tigecycline resistance increased in all of the hospitals, 
within the two year groups studied (5%, 3%, 12% and 1% 
increases). Although the proportions of resistant isolates 
within each antibiotic category differed for both year 
cohorts, no significant difference could be determined 
between the hospital site and resistance to each agent 
(P<0.05; Kruskal wallis).  
 
Molecular Analysis of Resistance Determinants 
Multiplex PCR and agarose gel electrophoresis allowed 
for the amplification and separation of three different 
ESBL resistance determinants, namely TEM, SHV and CTX, 
(Figure 4). In 2010 9% (n=20) of the isolates and 22% 
(n=54) of the isolates in 2012 expressed TEM alone, 
compared to 1% (n=2, 2010) and 2% (n=4, 2012) for SHV 
and 38% (n=87, 2010) and 27% (n=66, 2012) for CTX. 
Dual expression of CTX and TEM was observed in 34% 
(n=79, 2010) and 23% (n=58, 2012) of the isolates, 6% 
(n=13, 2010) and 2% (n=5, 2012) were observed to 
express TEM and SHV and within 2012 alone 3% (n=3) of 
the isolates demonstrated joint resistance with CTX and 
SHV. One isolate in 2010 and 4 in 2012 expressed all three 
resistance enzymes and 12% (n=27, 2010) and 21% 
(n=54, 2012) of the isolates demonstrated negative 
results for multiplex PCR analysis.  
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(a)                                                                                                      (b) 
 
Figure 3: Percentage resistance against each of the antimicrobial agents tested according to the hospital site within (a) 
2010 and (b) 2012. Results indicate that overall resistance is increasing however greater resistance within certain 
hospitals could be determined within co-amoxiclav, tigecycline, meropenem and ertapenem.  
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Figure 4: Example of a multiplex PCR analysis for the detection of the SHV, CTX and TEM resistance determinants, lane 
one illustrates the gene markers, 2-14 sample analysis and lane 15 the negative control. 
 
 
Although a significant proportion of the isolates were 
responsible for infections in female patients, no 
significant differences could be determined between 
resistance determinant and patient gender or hospital site 
(P>0.05; Mann-Whitney). In the 2010 cohort a 
relationship between patient age and joint expression of 
the TEM and SHV determinants was revealed by a 
Spearman correlation (P0.0174). The same correlation 
was not evident in 2012, as resistance had spread to age 
groups 0-10 and 30-40. In 2012 a similar relationship was 
observed between patient age and joint CTX and SHV 
expression (Spearman correlation, p0.0221).  
 
Discussion 
This study aimed to evaluate the profile of ESBL 
producing bacteria in the Hampshire county and identify 
relationships between ESBL, AmpC or dual resistance, the 
patient demographic and antimicrobial prescribing, to 
highlight potential shifts in antimicrobial resistance. The 
results obtained have identified some significant findings 
including an increase in antimicrobial resistance in nine 
of the thirteen antibiotics studied and potential 
relationships between resistance determinant and patient 
age. 
 
The organism identification and patient demographic 
within the Hampshire area corresponded to previous 
studies. Results compare to a number of published data 
including those by Kassakian, et al. who described mean 
patient ages of 69, 70 and 65, with E.coli presenting as the 
most common bacterial species and urinary tract 
infections being the most predominant infection type 
[17].  
The preponderance of isolates collected from female 
patients suggested an increase susceptibility to multi-
resistant infection. Nevertheless the predominant 
infection site in both year cohorts was the urinary tract 
and, with evidence suggesting that half the female 
population will suffer a UTI during their lifetime, this 
could be testament to why a higher number of female 
infections were observed [18].  
 
A significant number of patients within each year 
cohort reported as receiving no previous antimicrobial 
therapy. Further scrutiny of this information revealed 
that patients presenting within the community had a 
lower mean age compared to the total age. This implies 
that these patients fall within younger age groups, with 
potentially lower risk of predisposing illness prior to 
experiencing an ESBL infection. While previous 
antimicrobial therapy has been identified as a risk factor 
for ESBL production, this information suggests that a 
significant proportion of patients within this county do 
not fall within this patient demographic. In contrast 
patients presenting within the nosocomial environment 
demonstrated higher age groups compared to the total 
mean age, implying an increased risk of predisposing 
pathologies and potential immuno-compromisation 
resulting in an increased risk of multi-resistant infection. 
 
An increase in prevalence of ESBL infections within 
the community setting was identified. This result was 
supported by previous research illustrating that ESBL 
resistance is not only a concern in the hospital 
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environment but within the community setting. No 
statistically significant relationships could be identified 
between age and resistance mechanisms, nevertheless 
further analysis revealed that within both year cohorts 
patients aged 1-10 appeared to have increased prevalence 
of AmpC infections. Further research should be initiated 
to identify potential risk factors, including intestinal 
carriage, with an aim to reduce AmpC infections within 
this age group. The most striking observation was the 
increase in prevalence of ESBL infections across all age 
ranges, implying that ESBL infections are increasing each 
year within the Hampshire County.  
 
Antibiotic susceptibility investigations identified an 
increase in resistance in nine of the thirteen antibiotics 
studied, of these amoxicillin demonstrated the highest 
levels of resistance and meropenem the least. Amoxicillin 
has been widely utilised for the treatment of UTI's, 
potentially increasing resistance. The National Institute 
for Health and Care Excellence (NICE) guidelines now 
only recommend the use of amoxicillin for the treatment 
of asymptomatic bacteriuria in pregnancy [19]. In 
contrast meropenem is reserved for patients suffering 
sepsis and, in comparison is used to a lesser extent.  
 
Information from the primary care trust prescribing 
data for Hampshire was collected to evaluate 
antimicrobial resistance to prescribing quantities. A 
significant increase in antimicrobial prescriptions was 
identified between the first quarter of 2010-2011 and the 
fourth quarter of 2011-2012 (186,465 to 325,909). 
Hospital prescribing policies were also scrutinised to 
distinguish if prescribing in the nosocomial environment 
could potentially contributed to increases in resistance. 
Agents demonstrating increased resistance such as 
augmentin and gentamicin were listed in two or more 
policies. In contrast ertapenem, identified as an agent 
with a reduction in resistance was only listed within one 
hospital prescribing policy. Applying this theory to the 
increased resistance of tigecycline was challenging as this 
agent was, at the time, seldom used within the Hampshire 
county. Previous research nevertheless has identified 
spontaneous mutations resulting in reduced susceptibility 
to tigecycline within E.coli and Klebsiella pneumoniae 
isolates [20,21]. Prescribing of individual agents within 
the community was also investigated through the 
prescribing by GP practice database, held by the Health 
and Social Care Information Centre. During the month of 
June 2010, 2636 doses of augmentin were prescribed, this 
increased to 2953 in 2012, implying that an increase in 
prescribing may contribute to antimicrobial resistance. In 
contrast prescriptions for ciprofloxacin, an agent 
demonstrating a reduction in resistance, rose by only 112 
between 2010 and 2012 (1578 to 1690). Although an 
increase in prescriptions was identified, the number 
prescribed was significantly lower than those of 
augmentin, suggesting that ciprofloxacin is used to a 
lesser extent. These observations reinforce the 
importance of the regular review of antimicrobial 
prescribing policies. Regularly rotating agents may 
plausibly aid in the reduction of antimicrobial resistance. 
 
A significant correlation was identified between 
patient age and TEM and SHV expression in the 2010 
cohort and between CTX and SHV in 2012. These findings 
suggest that resistance determinants may initially present 
within the elderly population and in time increase to a 
more diverse age range. 
 
To conclude, this study has identified an increase in 
ESBL prevalence in the nosocomial and community 
settings. An increased prevalence of AmpC was identified 
in younger patients and resistance determinant 
expression potentially emerged in the elderly population, 
then diversified through all ages. An increase in antibiotic 
resistance escalates the importance of timely diagnosis 
and prompt appropriate treatment. Over prescribing of 
agents may contribute to increased resistance. Action 
should be taken with regards to antimicrobial 
stewardship to reduce prescriptions for unnecessary 
cases, potentially reducing resistance.  
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